# Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23)

> **NCT06289868** · — · COMPLETED · sponsor: **Beckman Coulter, Inc.** · enrollment: 1409 (actual)

## Conditions studied

- HAV

## Interventions

- **DIAGNOSTIC_TEST:** Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
- **DIAGNOSTIC_TEST:** Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays

## Key facts

- **NCT ID:** NCT06289868
- **Lead sponsor:** Beckman Coulter, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-27
- **Primary completion:** 2024-08-13
- **Final completion:** 2024-08-29
- **Target enrollment:** 1409 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06289868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06289868, "Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06289868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*